Guidance and quality standards Awaiting development

Showing 311 to 317 of 317

Guidance and quality standards awaiting development
Title	Type
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477	Technology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments TS ID 11952	Technology appraisal guidance
Zavegepant for treating acute migraine TSID 11998	Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]	Technology appraisal guidance
Zuranolone for treating severe postnatal depression ID6431	Technology appraisal guidance